Empagliflozin—A New Chance for Patients with Chronic Heart Failure

Empagliflozin—A New Chance for Patients with Chronic Heart Failure

The heart failure (HF) epidemic is one of the challenges that has been faced by the healthcare system worldwide for almost 25 years. With an ageing world population and a fast-paced lifestyle that promotes the development of cardiovascular disease, the number of people suffering from heart failure w...

Full description

Bibliographic Details
Main Authors:	Klaudia Kowalska, Justyna Walczak, Joanna Femlak, Ewelina Młynarska, Beata Franczyk, Jacek Rysz
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	Pharmaceuticals
Subjects:	heart failure cardiovascular pharmacotherapy cardioprotection SGLT2 inhibitors empagliflozin cardiovascular diseases
Online Access:	https://www.mdpi.com/1424-8247/15/1/47

Similar Items

Empagliflozin and the Prevention of Heart Failure
by: Douglas L. Mann, MD, et al.
Published: (2017-08-01)

Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial
by: Andrea Natali, et al.
Published: (2017-10-01)

Effect of empagliflozin on left ventricular contractility and peak oxygen uptake in subjects with type 2 diabetes without heart disease: results of the EMPA-HEART trial
by: Lorenzo Nesti, et al.
Published: (2022-09-01)

Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
by: Ampudia-Blasco FJ, et al.
Published: (2017-01-01)

Empagliflozin Reduces Interleukin-6 Levels in Patients with Heart Failure
by: Michael Gotzmann, et al.
Published: (2023-07-01)

Cell-Target-Specific Anti-Inflammatory Effect of Empagliflozin: In Vitro Evidence in Human Cardiomyocytes
by: Silvia Giannattasio, et al.
Published: (2022-05-01)

Effect of high-fat diet and empagliflozin on cardiac proteins in mice
by: Xiaoyu Pan, et al.
Published: (2022-10-01)

New Insights into the Use of Empagliflozin—A Comprehensive Review
by: Joanna Forycka, et al.
Published: (2022-12-01)

Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA‐REG OUTCOME trial
by: David Fitchett, et al.
Published: (2021-12-01)

Comparative Efficacy of Dapagliflozin and Empagliflozin of a Fixed Dose in Heart Failure: A Network Meta-Analysis
by: Zepeng Shi, et al.
Published: (2022-04-01)

Angiotensin pathways under therapy with empagliflozin in patients with chronic heart failure
by: Agnes Bosch, et al.
Published: (2023-06-01)

Empagliflozin: a potential anticancer drug
by: Wenwen Wu, et al.
Published: (2023-07-01)

Empagliflozin in Adults with Chronic Kidney Disease (CKD): Current Evidence and Place in Therapy
by: Colbert GB, et al.
Published: (2023-02-01)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
by: Nikole J. Byrne, BSc, et al.
Published: (2017-08-01)

Effect of Empagliflozin and Dapagliflozin on Ambulatory Arterial Stiffness in Patients with Type 2 Diabetes Mellitus and Cardiovascular Co-Morbidities: A Prospective, Observational Study
by: Dimitrios Patoulias, et al.
Published: (2022-08-01)

Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells
by: Sha Chen, et al.
Published: (2023-07-01)

[Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy]
by: Sergio Iannazzo, et al.
Published: (2016-03-01)

Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01)

A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES
by: M. V. Amosova, et al.
Published: (2017-12-01)

Comparison of Extraglycemic effects of Dapagliflozin and Empagliflozin
by: Haroon Aziz, et al.
Published: (2023-06-01)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
by: Atsushi Tanaka, et al.
Published: (2020-11-01)

Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
by: Shih-Jie Jhuo, et al.
Published: (2021-06-01)

Design and rationale of the EMPA‐VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure
by: Moritz J. Hundertmark, et al.
Published: (2021-08-01)

The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
by: Hsiang-Chun Lee, et al.
Published: (2019-04-01)

Empagliflozin reduces markers of acute kidney injury in patients with acute decompensated heart failure
by: Kirsten Thiele, et al.
Published: (2022-08-01)

Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
by: Julian Wolfes, et al.
Published: (2024-02-01)

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved
by: Andrew J.S. Coats, et al.
Published: (2024-02-01)

The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives
by: Joaquim Barreto, et al.
Published: (2023-09-01)

SGLT2 Inhibitors in Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials
by: Noor Ul Amin, et al.
Published: (2022-11-01)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
by: Klaudia Kowalska, et al.
Published: (2022-12-01)

Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
by: Phyo T. Htoo, et al.
Published: (2024-02-01)

Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
by: Liu Y, et al.
Published: (2021-05-01)

Effects of the sodium‐glucose cotransporter 2 inhibitor empagliflozin on vascular function in patients with chronic heart failure
by: Julie Kolwelter, et al.
Published: (2021-12-01)

Empagliflozin: a new strategy for nephroprotection in diabetes
by: Anton Ivanovich Korbut, et al.
Published: (2017-05-01)

Association between Empagliflozin Use and Electrocardiographic Changes
by: Daniel Antwi-Amoabeng, et al.
Published: (2022-07-01)

Novel cardioprotective mechanism for Empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia
by: Ruhua Deng, et al.
Published: (2022-10-01)

Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat
by: Sin-Hee Park, et al.
Published: (2020-02-01)

SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
by: Chenguang Li, et al.
Published: (2019-02-01)

Effects of SGLT2 inhibition via empagliflozin on cognitive and physical impairment in frail diabetic elders with chronic kidney disease
by: Pasquale Mone, et al.
Published: (2024-02-01)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
by: Yixiang Xu, et al.
Published: (2023-04-01)